Nirsevimab is Effective Against Respiratory Syncytial Virus-Associated Hospitalization Among American Indian and Alaska Native Children in Their First and Second RSV Seasons in Alaska and the Southwest United States, 2023-2024: Erratum.

Saved in:
Bibliographic Details
Title: Nirsevimab is Effective Against Respiratory Syncytial Virus-Associated Hospitalization Among American Indian and Alaska Native Children in Their First and Second RSV Seasons in Alaska and the Southwest United States, 2023-2024: Erratum.
Authors: Hammitt LL, Espinoza JS, Keck JW, Hartman RM, Alvarez-Colon G, Burrage A, Campbell AP, Cardona F, Chappell J, Christensen L, Dawood FS, Desnoyers C, Dobson J, Halasa N, Hurley C, Larsen R, McAuley JB, McMorrow ML, Menachof K, Prill M, Oxley L, Parker Riley D, Ritchie N, Sandoval M, Singleton RJ, Sutcliffe CG
Source: The Pediatric infectious disease journal [Pediatr Infect Dis J] 2026 Apr 01; Vol. 45 (4), pp. 384. Date of Electronic Publication: 2026 Mar 10.
Publication Type: Journal Article
Journal Info: Publisher: Williams & Wilkins Country of Publication: United States NLM ID: 8701858 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-0987 (Electronic) Linking ISSN: 08913668 NLM ISO Abbreviation: Pediatr Infect Dis J Subsets: MEDLINE; In Process
Database: MEDLINE Ultimate
Description
ISSN:1532-0987
DOI:10.1097/INF.0000000000005155